FDA Approves X4 Pharmaceuticals' Xolremdi (Mavorixafor) Capsules For Use In Patients 12 Years Of Age And Older With WHIM Syndrome To Increase The Number Of Circulating Mature Neutrophils And Lymphocytes
美国食品药品管理局批准X4制药公司的Xolremdi(Mavorixafor)胶囊,用于12岁及以上的WHIM综合征患者,以增加循环中的成熟中性粒细胞和淋巴细胞的数量